Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of “Hold” by Analysts

Sage Therapeutics, Inc. (NASDAQ:SAGE) has received an average recommendation of “Hold” from the nineteen ratings firms that are presently covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and two have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $8.81.

Several research firms have recently issued reports on SAGE. Canaccord Genuity Group decreased their price target on Sage Therapeutics from $9.00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, February 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $12.00 price objective (down previously from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Wedbush reiterated a “neutral” rating and issued a $6.00 target price on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of Sage Therapeutics in a research note on Friday, April 25th. Finally, Bank of America started coverage on shares of Sage Therapeutics in a research report on Tuesday, March 11th. They set an “underperform” rating and a $5.00 price target on the stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC grew its holdings in shares of Sage Therapeutics by 57.7% in the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company’s stock worth $122,000 after acquiring an additional 8,228 shares during the last quarter. Inspire Investing LLC boosted its position in shares of Sage Therapeutics by 30.4% in the 4th quarter. Inspire Investing LLC now owns 75,313 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 17,541 shares during the period. Empowered Funds LLC purchased a new position in Sage Therapeutics in the 4th quarter worth about $91,000. Ieq Capital LLC purchased a new position in Sage Therapeutics in the 4th quarter worth about $57,000. Finally, US Bancorp DE raised its holdings in Sage Therapeutics by 22.3% during the 4th quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 2,268 shares during the period. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Trading Down 4.6%

NASDAQ SAGE opened at $6.80 on Friday. The company has a 50-day moving average price of $7.38 and a two-hundred day moving average price of $6.73. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $13.47. The stock has a market cap of $425.82 million, a price-to-earnings ratio of -1.03 and a beta of 0.20.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The business had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. During the same quarter in the prior year, the firm posted ($1.80) earnings per share. The business’s quarterly revenue was up 78.0% on a year-over-year basis. As a group, equities research analysts expect that Sage Therapeutics will post -3.52 earnings per share for the current fiscal year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.